Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : MILs were successfully grown for all solid tumor types evaluated, including NSCLC, prostate, SCCHN, GBM and breast cancer and expanded MILs from the bone marrow of all patients contained cytokine-producing shared tumor antigen-specific T cells.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 11, 2020
Details : Phase 2a clinical trial will assess the safety and efficacy of MILs in patients with locally advanced unresectable or metastatic NSCLC who have relapsed on, an anti-PD-1-containing regimen.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 21, 2020
Reset All
